Quadrature Capital Ltd Sells 23,879 Shares of The Chemours Company (NYSE:CC)

Quadrature Capital Ltd cut its stake in The Chemours Company (NYSE:CC) by 67.3% during the third quarter, HoldingsChannel reports. The fund owned 11,624 shares of the specialty chemicals company’s stock after selling 23,879 shares during the quarter. Quadrature Capital Ltd’s holdings in Chemours were worth $236,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the stock. Matrix Trust Co purchased a new position in Chemours in the third quarter valued at about $25,000. Blue Trust Inc. grew its position in shares of Chemours by 166.9% in the 3rd quarter. Blue Trust Inc. now owns 1,169 shares of the specialty chemicals company’s stock worth $26,000 after buying an additional 731 shares during the last quarter. Truvestments Capital LLC bought a new position in shares of Chemours during the 3rd quarter worth approximately $35,000. Brooklyn Investment Group purchased a new stake in Chemours during the third quarter valued at approximately $37,000. Finally, Signaturefd LLC lifted its position in Chemours by 163.7% during the third quarter. Signaturefd LLC now owns 1,959 shares of the specialty chemicals company’s stock valued at $40,000 after acquiring an additional 1,216 shares during the last quarter. 76.26% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Barclays upped their price target on Chemours from $21.00 to $23.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. Morgan Stanley decreased their price target on Chemours from $30.00 to $25.00 and set an “equal weight” rating for the company in a research note on Tuesday, November 5th. Royal Bank of Canada dropped their price target on Chemours from $28.00 to $25.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. The Goldman Sachs Group decreased their price objective on shares of Chemours from $29.00 to $23.00 and set a “neutral” rating for the company in a research report on Tuesday, September 3rd. Finally, BMO Capital Markets boosted their target price on shares of Chemours from $30.00 to $32.00 and gave the stock an “outperform” rating in a research report on Monday, October 7th. Five analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, Chemours presently has a consensus rating of “Hold” and an average price target of $24.88.

Insider Transactions at Chemours

In other Chemours news, SVP Alvenia Scarborough sold 7,500 shares of the company’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $20.64, for a total value of $154,800.00. Following the completion of the transaction, the senior vice president now owns 16,645 shares in the company, valued at approximately $343,552.80. This represents a 31.06 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.47% of the company’s stock.

Chemours Price Performance

Shares of NYSE:CC opened at $21.17 on Wednesday. The Chemours Company has a twelve month low of $15.10 and a twelve month high of $32.70. The company has a current ratio of 1.73, a quick ratio of 0.92 and a debt-to-equity ratio of 6.05. The company has a market cap of $3.16 billion, a PE ratio of 42.34 and a beta of 1.80. The company’s 50 day moving average is $19.93 and its 200 day moving average is $20.92.

Chemours (NYSE:CC) last released its quarterly earnings data on Monday, November 4th. The specialty chemicals company reported $0.40 earnings per share for the quarter, topping analysts’ consensus estimates of $0.32 by $0.08. The firm had revenue of $1.50 billion for the quarter, compared to analyst estimates of $1.44 billion. Chemours had a net margin of 1.34% and a return on equity of 29.48%. The business’s quarterly revenue was up .9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.64 earnings per share. On average, sell-side analysts forecast that The Chemours Company will post 1.35 EPS for the current year.

Chemours Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 16th. Stockholders of record on Friday, November 15th will be issued a $0.25 dividend. The ex-dividend date of this dividend is Friday, November 15th. This represents a $1.00 annualized dividend and a dividend yield of 4.72%. Chemours’s dividend payout ratio (DPR) is presently 200.00%.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.